FLOPROPIONE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C9H10O4
Molecular Weight	182.1733
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCC(=O)C1=C(O)C=C(O)C=C1O

InChI

InChIKey=PTHLEKANMPKYDB-UHFFFAOYSA-N

InChI=1S/C9H10O4/c1-2-6(11)9-7(12)3-5(10)4-8(9)13/h3-4,10,12-13H,2H2,1H3

HIDE SMILES / InChI

Description
Sources: http://eisai.jp/medical/products/di/EPI/CSP_C_EPI.pdf

Flopropione is an antispasmodic agent developed to relieve spasms in patients with hepatobiliary disorders, pancreatitis and urinary calculus. The mode of action is based on the inhibition of catechol-o-methyl-transferase (COMT), resulting in an adrenergic action, and anti-serotonin action. The current marketing status of the drug is unknown and considered to be "discontinued".

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Catechol O-methyltransferase 21 Target ID: P21964 Gene ID: 1312.0 Gene Symbol: COMT Target Organism: Homo sapiens (Human) Sources: http://eisai.jp/medical/products/di/EPI/CSP_C_EPI.pdf	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Biliary dyskinesia 1 Sources: http://eisai.jp/medical/products/di/EPI/CSP_C_EPI.pdf	Primary	Approved 8583	COSPANON Approved Use Antispasmodic effect resulting from the following diseases: Hepatobiliary disorders: biliary dyskinesia, cholelithiasis, cholecystitis, cholangitis and post-cholecystectomy síndrome; Pancreatic disease: pancreatitis Urinary calculus. Launch Date 1975
Cholelithiasis 14 Sources: http://eisai.jp/medical/products/di/EPI/CSP_C_EPI.pdf	Primary	Approved 8583	COSPANON Approved Use Antispasmodic effect resulting from the following diseases: Hepatobiliary disorders: biliary dyskinesia, cholelithiasis, cholecystitis, cholangitis and post-cholecystectomy síndrome; Pancreatic disease: pancreatitis Urinary calculus. Launch Date 1975
Cholecystitis 12 Sources: http://eisai.jp/medical/products/di/EPI/CSP_C_EPI.pdf	Primary	Approved 8583	COSPANON Approved Use Antispasmodic effect resulting from the following diseases: Hepatobiliary disorders: biliary dyskinesia, cholelithiasis, cholecystitis, cholangitis and post-cholecystectomy síndrome; Pancreatic disease: pancreatitis Urinary calculus. Launch Date 1975
Cholangitis 4 Sources: http://eisai.jp/medical/products/di/EPI/CSP_C_EPI.pdf	Primary	Approved 8583	COSPANON Approved Use Antispasmodic effect resulting from the following diseases: Hepatobiliary disorders: biliary dyskinesia, cholelithiasis, cholecystitis, cholangitis and post-cholecystectomy síndrome; Pancreatic disease: pancreatitis Urinary calculus. Launch Date 1975
Post-cholecystectomy syndrome 2 Sources: http://eisai.jp/medical/products/di/EPI/CSP_C_EPI.pdf	Primary	Approved 8583	COSPANON Approved Use Antispasmodic effect resulting from the following diseases: Hepatobiliary disorders: biliary dyskinesia, cholelithiasis, cholecystitis, cholangitis and post-cholecystectomy síndrome; Pancreatic disease: pancreatitis Urinary calculus. Launch Date 1975
Pancreatitis 16 Sources: http://eisai.jp/medical/products/di/EPI/CSP_C_EPI.pdf	Primary	Approved 8583	COSPANON Approved Use Antispasmodic effect resulting from the following diseases: Hepatobiliary disorders: biliary dyskinesia, cholelithiasis, cholecystitis, cholangitis and post-cholecystectomy síndrome; Pancreatic disease: pancreatitis Urinary calculus. Launch Date 1975
Urinary calculus 3 Sources: http://eisai.jp/medical/products/di/EPI/CSP_C_EPI.pdf	Primary	Approved 8583	COSPANON Approved Use Antispasmodic effect resulting from the following diseases: Hepatobiliary disorders: biliary dyskinesia, cholelithiasis, cholecystitis, cholangitis and post-cholecystectomy síndrome; Pancreatic disease: pancreatitis Urinary calculus. Launch Date 1975

C_max

Value	Dose	Co-administered	Analyte	Population
9 μg/mL OTHER GOV'T https://www.info.pmda.go.jp/go/interview/1/170033_1249007F1032_1_008_1F.pdf#page=18	240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered:		FLOPROPIONE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
80 mg 3 times / day multiple, oral Recommended Dose: 80 mg, 3 times / day Route: oral Route: multiple Dose: 80 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/25869815/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/25869815/	Sources: https://pubmed.ncbi.nlm.nih.gov/25869815/

PubMed

Title	Date	PubMed
Facilitation of expulsion of ureteral stones by addition of α1-blockers to conservative therapy.	2010-12	20604720
Positively charged calcium phosphate/polymer nanoparticles for photodynamic therapy.	2010-03	19924519
Different measures of molecular mobility: comparison between calorimetric and thermally stimulated current relaxation times below Tg and correlation with dielectric relaxation times above Tg.	2008-10	18271035
Prediction of onset of crystallization from experimental relaxation times. II. Comparison between predicted and experimental onset times.	2008-01	17854050
Predictions of onset of crystallization from experimental relaxation times I-correlation of molecular mobility from temperatures above the glass transition to temperatures below the glass transition.	2006-10	16933094

Patents

Sample Use Guides

In Vivo Use Guide

The usual adult dosage for oral use is 1 to 2 capsules (40-80 mg of flopropione) three times daily after meals.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Name

Type

Language

FLOPROPIONE

Official Name

English

EPHTANON

Preferred Name

English

FLOPROPIONE [MART.]

Common Name

English

Flopropione [WHO-DD]

Common Name

English

FLOPROPIONE [JAN]

Common Name

English

NSC-97909

Code

English

flopropione [INN]

Common Name

English

FLOPROPIONE [MI]

Common Name

English

2',4',6'-TRIHYDROXYPROPIOPHENONE

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29698